
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
Keywords: بواسیزوماب; Docetaxel; Epirubicin; Bevacizumab; MBC; CTC;